Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine*

Joe Brierley, MD; Joseph A. Carcillo, MD; Karen Choong, MD; Tim Cornell, MD; Allan DeCaen, MD; Andreas Deymann, MD; Allan Doctor, MD; Alan Davis, MD; John Duff, MD; Marc-Andre Dugas, MD; Alan Duncan, MD; Barry Evans, MD; Jonathan Feldman, MD; Kathryn Felmet, MD; Gene Fisher, MD; Lorry Frankel, MD; Howard Jeffries, MD; Bruce Greenwald, MD; Juan Gutierrez, MD; Mark Hall, MD; Yong Y. Han, MD; James Hanson, MD; Jan Hazelzet, MD; Lynn Hernan, MD; Jane Kiff, MD; Niranjani Kissoon, MD; Alexander Kon, MD; Jose Irazusta, MD; John Lin, MD; Angie Lorts, MD; Michelle Mariscalco, MD; Renuka Mehta, MD; Simon Nadel, MD; Trung Nguyen, MD; Carol Nicholson, MD; Mark Peters, MD; Regina Okhuysen-Cawley, MD; Tom Poulton, MD; Monica Relvs, MD; Agustin Rodriguez, MD; Ranna Rozenfeld, MD; Eduardo Schnitzler, MD; Tom Shanley, MD; Sara Skache, MD; Peter Skippen, MD; Adalberto Torres, MD; Bettina von Dessauer, MD; Jacki Weingarten, MD; Timothy Yeh, MD; Arno Zaritsky, MD; Bonnie Stojadinovic, MD; Jerry Zimmerman, MD; Aaron Zuckerberg, MD

Background: The Institute of Medicine calls for the use of clinical guidelines and practice parameters to promote “best practices” and to improve patient outcomes.


Participants: Society of Critical Care Medicine members with special interest in neonatal and pediatric septic shock were identified from general solicitation at the Society of Critical Care Medicine Educational and Scientific Symposia (2001–2006).

Methods: The Pubmed/MEDLINE literature database (1966–2006) was searched using the keywords and phrases: sepsis, septicemia, septic shock, endotoxemia, persistent pulmonary hypertension, nitric oxide, extracorporeal membrane oxygenation (ECMO), and American College of Critical Care Medicine guidelines. Best practice centers that reported best outcomes were identified and their practices examined as models of care. Using a modified Delphi method, 30 experts graded new literature. Over 30 additional experts then reviewed the updated recommendations. The document was subsequently modified until there was greater than 90% expert consensus.

Results: The 2002 guidelines were widely disseminated, translated into Spanish and Portuguese, and incorporated into Society of Critical Care Medicine and AHA sanctioned recommendations. Centers that implemented the 2002 guidelines reported best practice outcomes (hospital mortality 1%–5% in previously healthy, and 7%–10% in chronically ill children). Early use of 2002 guidelines was associated with improved outcome in the community hospital emergency department (number needed to treat = 3.3) and tertiary pediatric intensive care setting (number needed to treat = 3.6); every hour that went by without guideline adherence was associated with a 1.4-fold increased mortality risk. The updated 2007 guidelines continue to recognize an increased likelihood that children with septic shock, compared with adults, require 1) proportionally larger quantities of fluid, 2) inotrope and vasodilator therapies, 3) hydrocortisone for absolute adrenal insufficiency, and 4) ECMO for refractory shock. The major new recommendation in the 2007 update is earlier use of inotrope support through peripheral access until central access is attained.

Conclusion: The 2007 update continues to emphasize early use of age-specific therapies to attain time-sensitive goals, specifically recommending 1) first hour fluid resuscitation and inotropic therapy directed to goals of threshold heart rates, normal blood pressure, and capillary refill ≤2 secs, and 2) subsequent intensive care unit hemodynamic support directed to goals of central venous oxygen saturation >70% and cardiac index 3.3–6.0 L/min/m². (Crit Care Med 2009; 37:666–688)

Key Words: guidelines; sepsis; severe sepsis

*See also p. 785.

The American College of Critical Care Medicine (ACCM), which honors individuals for their achievements and contributions to multidisciplinary critical care medicine, is the consultative body of the Society of Critical Care Medicine (SCCM) that possesses recognized expertise in the practice of critical care. The College has developed administrative guidelines and clinical practice parameters for the critical care practitioner. New guidelines and practice parameters are continually developed, and current ones are systematically reviewed and revised.

Dr. Brierley received travel expenses from USCOM Ltd. Dr. Nadel has consulted, received honoraria, and study funding from Eli Lilly. Dr. Shanley has received a research grant from the National Institutes of Health. The remaining authors have not disclosed any potential conflicts of interest.

For information regarding this article, E-mail: carcilloja@ccm.upmc.edu

Copyright © 2009 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins

DOI: 10.1097/CCM.0b013e31819323c6
Neonatal and pediatric severe sepsis outcomes were already improving before 2002 with the advent of neonatal and pediatric intensive care (reduction in mortality from 97% to 9%) (1–4), and were markedly better than in adults (9% compared with 28% mortality) (3). In 2002, the American College of Critical Care Medicine (ACCM) Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Shock (5) were published, in part, to replicate the reported outcomes associated with implementation of “best clinical practices” (mortality rates of 0%–5% in previously healthy [6–8] and 10% in chronically ill children with septic shock [8]). There are two purposes served by this 2007 update of these 2002 clinical practice parameters. First, this 2007 document examines and grades new studies performed to test the utility and efficacy of the 2002 recommendations. Second, this 2007 document examines and grades relevant new treatment and outcome studies to determine to what degree, if any, the 2002 guidelines should be modified.

METHODS

More than 30 clinical investigators and clinicians affiliated with the Society of Critical Care Medicine who had special interest in hemodynamic support of pediatric patients with sepsis volunteered to be members of the “update” task force. Subcommittees were formed to review and grade the literature using the evidence-based scoring system of the ACCM. The literature was accrued, in part, by searching Pubmed/MEDLINE using the following keywords and phrases: sepsis, septicemia, septic shock, endotoxemia, persistent pulmonary hypertension (PPHN), nitric oxide (NO), and extracorporeal membrane oxygenation (ECMO). The search was narrowed to identify studies specifically relevant to children. Best practice outcomes were identified and described; clinical practice in these centers was used as a model.

The clinical parameters and guidelines were drafted and subsequently revised using a modification of the Delphi method. Briefly, the initial step included review of the literature and grading of the evidence by topic-based subcommittees during a 6-month period. Subcommittees were formed according to participant interest in each subtopic. The update recommendations from each subcommittee were incorporated into the preexisting 2002 document by the task force chairperson. All members commented on the unified update draft, and modifications were made in an iterative fashion until <10% of the task force disagreed with any specific or general recommendation. This process occurred during a 1-year period. Reviewers from the ACCM then requested further modifications that were considered for inclusion if supported by evidence and best practice. Grading of the literature and levels of recommendations were based on published ACCM criteria (Table 1).

RESULTS

Successful Dissemination, Acceptance, Implementation, and Outcome of 2002 Guidelines

The 2002 guidelines were initially distributed in the English language with official sanctioning by the Society for Critical Care Medicine with publication in Critical Care Medicine. The main pediatric algorithm was included in the Pediatric Advanced Life Support (PALS) manual published by the American Heart Association. In addition, the pediatric and newborn treatment algorithms were published in whole or part in multiple textbooks. The guidelines were subsequently published in Spanish and Portuguese allowing for dissemination in much of the American continents. There have been 57 peer-reviewed publications since 2002 that have cited these guidelines. Taken together these findings demonstrate academic acceptance and dissemination of the 2002 guidelines (Tables 2 and 3).

Many studies have tested the observations and recommendations of the 2002 guidelines. These studies reported evidence that the guidelines were useful and effective without any evidence of harm. For example, Wills et al (9) demonstrated near 100% survival when fluid resuscitation was provided to children with den-
Cold or warm shock

Decreased perfusion manifested by altered decreased mental status, capillary refill >2 secs (cold shock) or flush capillary refill (warm shock), diminished (cold shock) or bounding (warm shock) peripheral pulses, mottled cool extremities (cold shock), or decreased urine output <1 mL/kg/h

Fluid-refractory/ Catecholamine-resistant shock

Shock persists despite ≥60 mL/kg fluid resuscitation (when appropriate) and dopamine infusion to 10 μg/kg/min

Catecholamine-resistant shock

Shock persists despite use of the direct-acting catecholamines; epinephrine or norepinephrine

Refractory shock

Shock persists despite goal-directed use of inotropic agents, vasopressors, vasodilators, and maintenance of metabolic (glucose and calcium) and hormonal (thyroid, hydrocortisone, insulin) homeostasis

<table>
<thead>
<tr>
<th>Table 3. Threshold heart rates and perfusion pressure</th>
<th>Mean Arterial Pressure-Central Venous Pressure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart Rate (bpm)</td>
<td>(mm Hg)</td>
</tr>
<tr>
<td>Term newborn</td>
<td>120–180</td>
</tr>
<tr>
<td>Up to 1 yr</td>
<td>120–180</td>
</tr>
<tr>
<td>Up to 2 yrs</td>
<td>120–160</td>
</tr>
<tr>
<td>Up to 7 yrs</td>
<td>100–140</td>
</tr>
<tr>
<td>Up to 15 yrs</td>
<td>90–140</td>
</tr>
</tbody>
</table>

hpm, beats per minute.


also used high flux continuous renal replacement therapy (CRRT) and fresh frozen plasma infusion directed to the goal of normal international normalized ratio (INR) (prothrombin time). In a U.S. child health outcomes database (Kids’ Inpatient Database or KID) analysis, hospital mortality from severe sepsis was recently estimated to be 4.2% (2.3% in previously healthy children, and 7.8% in children with chronic illness) (16), a decrease compared with 9% in 1999 (4). Taken together, these studies indirectly and directly support the utility and efficacy of implementation of the time-sensitive, goal-directed recommendations of the 2002 guidelines in the emergency/delivery room and pediatric intensive care unit/neonatal intensive care unit settings.

**New Major Recommendations in the 2007 Update**

Because of the success of the 2002 guidelines, the 2007 update compilation and discussion of the new literature were directed to the question of what changes, if any, should be implemented in the update. The members of the committee were asked whether there are clinical practices which the best outcome practices are using in 2007 that were not recommended in the 2002 guidelines and should be recommended in the 2007 guidelines? The changes recommended were few. Most importantly, there was no change in emphasis between the 2002 guidelines and the 2007 update. (The continued emphasis is directed to: 1) first hour fluid resuscitation and inotropic drug therapy directed to goals of threshold heart rates (HR), normal blood pressure, and capillary refill ≤2 secs, and 2) subsequent intensive care unit hemodynamic support directed to goals of ScvO2 ≥70% and cardiac index 3.3–6.0 L/min/m2. New recommendations in the 2007 update include the following: 1) The 2002 guidelines recommended not giving cardiovascular agents until central vascular access was attained. This was because there was and still is concern that administration of peripheral vasoactive agents (especially vasopressors) could result in peripheral vascular/tissue injury. However, after implementation of the 2002 guidelines, the literature showed that, depending on availability of skilled personnel, it could take two or more hours to establish central access. Because mortality went up with delay in time to inotrope drug use, the 2007 update now recommends use of peripheral inotropes (not vasopressors) until central access is attained. The committee continues to recommend close monitoring of the peripheral access site to prevent peripheral vascular/tissue injury; 2) The 2002 guidelines made no recommendations on what sedative/analgesic agent(s) to use to facilitate placement of central lines and/or intubation. Multiple editorialists and cohort studies have since reported that the use of etomidate was associated with increased severity of illness adjusted mortality in adults and children with septic shock. The 2007 update now states that etomidate is not recommended for children with septic shock unless it is used in a randomized controlled trial format. For now, the majority of the committee uses atropine and ketamine for invasive procedures in children with septic shock. Little experience is available with ketamine use in newborn septic shock and the committee makes no recommendation in this population; 3) Since 2002, cardiac output (CO) can be measured not only with a pulmonary artery catheter, but also with Doppler echocardiography, or a pulse index contour cardiac output catheter, or a femoral arterial thermodilution catheter. Titration of therapy to CO 3.3–6.0 L/min/m2 remains the goal in patients with persistent catecholamine resistant shock in 2007 guidelines. Doppler echocardiography can also be used to direct therapies to a goal of superior vena cava (SVC) flow >40 mL/min/kg in very low birth weight (VLBW) infants; 4) There are several new potential rescue therapies reported since the 2002 guidelines. In children, enoximone and levosimendan have been highlighted in case series and case reports. Unlike vasopressin, which had been suggested by some as a vasoplegia rescue therapy, these agents are suggested by some as recalcitrant cardiogenic shock rescue agents. In newborns, inhaled prostacyclin and intravenous (IV) adenosine were reportedly successful in refractory PPHN. The 2007 update recommends further evaluation of these new agents in appropriate patient settings; and 5) The 2002 guidelines made no recommendation on fluid removal. Although fluid resuscitation remains the hallmark and first step of septic shock resuscitation, two cohort studies showed the importance of fluid removal in fluid overloaded septic shock/multiple organ failure patients. The 2007 update recommends that fluid removal using diuretics, peritoneal dialysis, or CRRT is indicated in patients who have been adequately fluid resuscitated but cannot maintain subsequent even-fluid balance through native urine output. This can be done when such patients develop new onset hepatomegaly, rales, or 10% body weight fluid overload.

Table 2. American College of Critical Care Medicine hemodynamic definitions of shock

<table>
<thead>
<tr>
<th>Shock Type</th>
<th>Hemodynamic Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cold or warm shock</td>
<td>Decreased perfusion manifested by altered decreased mental status, capillary refill &gt;2 secs (cold shock) or flush capillary refill (warm shock), diminished (cold shock) or bounding (warm shock) peripheral pulses, mottled cool extremities (cold shock), or decreased urine output &lt;1 mL/kg/h</td>
</tr>
<tr>
<td>Fluid-refractory/ Catecholamine-resistant shock</td>
<td>Shock persists despite ≥60 mL/kg fluid resuscitation (when appropriate) and dopamine infusion to 10 μg/kg/min</td>
</tr>
<tr>
<td>Catecholamine-resistant shock</td>
<td>Shock persists despite use of the direct-acting catecholamines; epinephrine or norepinephrine</td>
</tr>
<tr>
<td>Refractory shock</td>
<td>Shock persists despite goal-directed use of inotropic agents, vasopressors, vasodilators, and maintenance of metabolic (glucose and calcium) and hormonal (thyroid, hydrocortisone, insulin) homeostasis</td>
</tr>
</tbody>
</table>

Copyright (c) Society of Critical Care Medicine and Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Mortality from fluid-refractory, dopamine-resistant septic shock in this study (18%) was markedly reduced compared with mortality in the 1985 study (58%) (29), in which aggressive fluid resuscitation was not used. Since 2002, investigators have used Doppler ultrasound to measure CO (34), and similarly reported that previously healthy children with meningococcemia often had a low CO with a high mortality rate, whereas CO was high and mortality rate was low in septic shock related to catheter-associated blood stream infections.

Neonatal septic shock can be complicated by the physiologic transition from fetal to neonatal circulation. In utero, 85% of fetal circulation bypasses the lungs through the ductus arteriosus and foramen ovale. This flow pattern is maintained by suprasystolic pulmonary vascular resistance in the prenatal period. At birth, inhalation of oxygen triggers a cascade of biochemical events that ultimately result in reduction in pulmonary vascular resistance and artery pressure and transition from fetal to neonatal circulation with blood flow now being directed through the pulmonary circulation. Closure of the ductus arteriosus and foramen ovale complete this transition. Pulmonary vascular resistance and artery pressures can remain elevated and the ductus arteriosus can remain open for the first 6 wks of life, whereas the foramen ovale may remain probe patent for years. Sepsis-induced acidosis and hypoxia can increase pulmonary vascular resistance and thus arterial pressure and maintain patency of the ductus arteriosus, resulting in PPHN of the newborn and persistent fetal circulation. Neonatal septic shock with PPHN can be associated with increased right ventricle work. Despite in utero conditioning, the thickened right ventricle may fail in the presence of systemic pulmonary artery pressures. Decompensated right ventricular failure can be clinically manifested by tricuspid regurgitation and hepatomegaly. Newborn animal models of group B streptococcal and endotoxin shock have also documented reduced CO, and increased pulmonary, mesenteric, and SVR (35–39). Therapies directed at reversal of right ventricle failure, through reduction of pulmonary artery pressures, are commonly needed in neonates with fluid-refractory shock and PPHN.

The hemodynamic response in preterm, VLBW infants with septic shock (<32 wks gestation, <1000 g) is least understood. Most hemodynamic information is derived only from echocardiographic evaluation and there are few septic shock studies in this population. Neonatology investigators often fold septic shock patients into “respiratory distress syndrome” and “shock” studies rather than conduct septic shock studies alone. Hence, the available clinical evidence on the hemodynamic response in premature infants for the most part is in babies with respiratory distress syndrome or shock of undescrbed etiology. In the first 24 hrs after birth during the “transitional phase,” the neonatal heart must rapidly adjust to a high vascular resistance state compared with the low resistance placenta. CO and blood pressure may decrease when vascular resistance is increased (40). However, the literature indicates that premature infants with shock can respond to volume and inotropic therapies with improved stroke volume (SV), contractility, and blood pressure (41–54).

Several other developmental considerations influence shock therapy in the premature infant. Relative initial deficiencies in the thyroid and parathyroid hormone axes have been reported and can result in the need for thyroid hormone and/or calcium replacement (55, 56). Hydrocortisone has been examined in this population as well. Since 2002, randomized controlled trials showed that prophylactic use of hydrocortisone on day 1 of life reduced the incidence of hypotension in this population, (57) and a 7-day course of hydrocortisone reduced the need for inotropes in VLBW infants with septic shock (58–60). Immature mechanisms of thermogenesis require attention to external warming. Reduced glycogen stores and muscle mass for gluconeogenesis require attention to maintenance of serum glucose concentration. Standard practices in resuscitation of preterm infants in septic shock use a more graded approach to volume resuscitation and vasopressor therapy compared with resuscitation of term neonates and children. This more cautious approach is a response to anecdotal reports that preterm infants at risk for intraventricular hemorrhage (<30 wks gestation) can develop hemorrhage after rapid shifts in blood pressure; however, some now question whether long-term neurologic outcomes are related to periventricular leukomalacia (a result of prolonged under perfusion) more than to intraventricular hemorrhage. Another complicating factor in VLBW infants is the persistence.
of the patent ductus arteriosus. This can occur because immature muscle is less able to constrict. The majority of infants with this condition are treated medically with indomethacin, or in some circumstances with surgical ligation. Rapid administration of fluid may further increase left to right shunting through the ductus with ensuing pulmonary edema.

One single-center randomized control trial reported improved outcome with use of daily 6-hr pentoxyfilline infusions in very premature infants with sepsis (61, 62). This compound is both a vasodilator and an anti-inflammatory agent. A Cochrane analysis agrees that this promising therapy deserves evaluation in a multicentered trial setting (63).

What Clinical Signs and Hemodynamic Variables Can Be Used to Direct Treatment of Newborn and Pediatric Shock?

Shock can be defined by clinical variables, hemodynamic variables, oxygen utilization variables, and/or cellular variables; however, after review of the literature, the committee continues to choose to define septic shock by clinical, hemodynamic, and oxygen utilization variables only. This decision may change at the next update. For example, studies demonstrate that blood troponin concentrations correlate well with poor cardiac function and response to inotropic support in children with septic shock (64–66). Lactate is recommended in adult septic shock laboratory testing bundles for both diagnosis and subsequent monitoring of therapeutic responses. However, most adult literature continues to define shock by clinical hypotension, and recommends using lactate concentration to identify shock in normotensive adults. For now the overall committee recommends early recognition of pediatric septic shock using clinical examination, not biochemical tests. Two members dissent and an anti-inflammatory agent. A Cochrane analysis agrees that this promising therapy deserves evaluation in a multicentered trial setting (63).

Shock can be defined by clinical variables, hemodynamic variables, oxygen utilization variables, and/or cellular variables; however, after review of the literature, the committee continues to choose to define septic shock by clinical, hemodynamic, and oxygen utilization variables only. This decision may change at the next update. For example, studies demonstrate that blood troponin concentrations correlate well with poor cardiac function and response to inotropic support in children with septic shock (64–66). Lactate is recommended in adult septic shock laboratory testing bundles for both diagnosis and subsequent monitoring of therapeutic responses. However, most adult literature continues to define shock by clinical hypotension, and recommends using lactate concentration to identify shock in normotensive adults. For now the overall committee recommends early recognition of pediatric septic shock using clinical examination, not biochemical tests. Two members dissent from this recommendation and suggest use of lactate as well.

Ideally, shock should be clinically diagnosed before hypotension occurs by clinical signs, which include hypothermia or hyperthermia, altered mental status, and peripheral vasodilation (warm shock) or vasoconstriction with capillary refill >2 secs (cold shock). Threshold HR associated with increased mortality in critically ill (not necessarily septic) infants are a HR <90 beats per minute (bpm) or >160 bpm, and in children are a HR <70 bpm or >150 bpm (67). Emergency department therapies should be directed toward restoring normal mental status, threshold HRs, peripheral perfusion (capillary refill <3 secs), palpable distal pulses, and normal blood pressure for age (Table 3) (11). Orr et al reported that specific hemodynamic abnormalities in the emergency department were associated with progressive mortality (in paraphrenthesis); eucardia (1%) < tachycardia/bradycardia (3%) < hypotension with capillary refill <3 secs (5%) < normotension with capillary refill greater than 3 secs (7%) < hypotension with capillary refill greater than 3 secs (33%). Reversal of these hemodynamic abnormalities using ACCM/PALS recommended therapy was associated with a 40% reduction in mortality odds ratio regardless of the stage of hemodynamic abnormality at the time of presentation (68). One member of the committee wishes to emphasize that these signs are important only if the patients are considered ill.

In both neonates and children, shock should be further evaluated and resuscitation treatment guided by hemodynamic variables including perfusion pressure (mean arterial pressure [MAP] minus central venous pressure) and CO. As previously noted, blood flow (Q) varies directly with perfusion pressure (∆P) and inversely with resistance (R). This is mathematically represented by Q = ∆P/R. For the systemic circulation this is represented by CO = (MAP – central venous pressure)/SVR. This relationship is important for organ perfusion. In the kidney, for example, renal blood flow = (mean renal arterial pressure – mean renal venous pressure)/renal vascular resistance. The kidney and brain have vasomotor autoregulation, which maintains blood flow in low blood pressure (MAP or renal arterial pressure) states. At some critical point, perfusion pressure is reduced below the ability of the organ to maintain blood flow.

One goal of shock treatment is to maintain perfusion pressure above the critical point below which blood flow cannot be effectively maintained in individual organs. The kidney receives the second highest blood flow relative to its mass of any organ in the body, and measurement of urine output (with the exception of patients with hyperosmolar states such as hyperglycemia which leads to osmotic diuresis) and creatinine clearance can be used as an indicator of adequate blood flow and perfusion pressure. Maintenance of MAP with norepinephrine has been shown to improve urine output and creatinine clearance in hyperdynamic sepsis (69). Producing a supranormal MAP above this point is likely not of benefit (70).

Reduction in perfusion pressure below the critical point necessary for adequate splanchic organ perfusion can also occur in disease states with increased intrathoracic pressure (IAP) such as bowel wall edema, ascites, or abdominal compartment syndrome. If this increased IAP is not compensated for by an increase in contractility that improves MAP despite the increase in vascular resistance, then splanchic perfusion pressure is decreased. Therapeutic reduction of IAP (measured by intrabladder pressure) using diuretics and/or peritoneal drainage for IAP >12 mm Hg, and surgical decompression for >30 mm Hg, results in restoration of perfusion pressure and has been shown to improve renal function in children with burn shock (71).

Normative blood pressure values in the VLBW newborn have been reassessed. A MAP <30 mm Hg is associated with poor neurologic outcome and survival, and is considered the absolute minimum tolerable blood pressure in the extremely premature infant (42). Because blood pressure does not necessarily reflect CO, it is recommended that normal CO and/or SVC flow, measured by Doppler echocardiography, be a primary goal as well (72–82).

Although perfusion pressure is used as a surrogate marker of adequate flow, the previous equation shows that organ blood flow (Q) correlates directly with perfusion pressure and inversely with vascular resistance. If the ventricle is healthy, an elevation of SVR results in hypertension with maintenance of CO. Conversely, if ventricular function is reduced, the presence of normal blood pressure with high vascular resistance means that CO is reduced. If the elevation in vascular resistance is marked, the reduction in blood flow results in shock.

A CI between 3.3 and 6.0 L/min/m² is associated with best outcomes in septic shock patients (21) compared with patients without septic shock for whom a CI above 2.0 L/min/m² is sufficient (83). Attainment of this CO goal is often dependent on attaining threshold HRs. However, if the HR is too high, then there is not enough time to fill the coronary arteries during diastole, and contractility and CO will decrease. Coronary perfusion
stress is too high due to an increased end-diastolic ventricular pressure and diastolic volume secondary to fluid overload, then a diuretic may be required to improve SV by moving leftward on the overfilled Starling function curve. The effectiveness of these maneuvers will similarly be evidenced by improvement in the HR/systolic blood pressure shock index, CO, and SVR along with improved distal pulses, skin temperature, and capillary refill.

Shock should also be assessed and treated according to oxygen utilization measures. Measurement of CO and \( O_2 \) consumption were proposed as being of benefit in patients with persistent shock because a CI between 3.3 and 6.0 L/min/m\(^2\) and \( O_2 \) consumption >200 mL/min/m\(^2\) are associated with improved survival (21). Low CO is associated with increased mortality in pediatric septic shock (20–29). In one study, children with fluid-refractory, dopamine-resistant shock were treated with goal-directed therapy (CI >3.3 and <6 L/min/m\(^2\)) and found to have improved outcomes compared with historical reports (29). Because low CO is associated with increased \( O_2 \) extraction, (22) \( ScvO_2 \) saturation can be used as an indirect indicator of whether \( CO \) is adequate to meet tissue metabolic demand. If tissue oxygen delivery is adequate, then assuming a normal arterial oxygen saturation of 100%, mixed venous saturation is >70%. Assuming a hemoglobin concentration of 10 g/dL and 100% arterial \( O_2 \) saturation then a CI >3.3 L/min/m\(^2\) with a normal oxygen consumption of 150 mL/min/m\(^2\) (\( O_2 \) consumption = CI x arterial \( O_2 \) content – venous \( O_2 \) content)) results in a mixed venous saturation of >70% because 150 mL/min/m\(^2\) = 3.3 L/min/m\(^2\) x \([1.39 \times 10 \text{ g/dL} + PaO_2 \times 0.003]\) \times 10 x [1 – 0.7]. In an emergency department study in adults with septic shock, maintenance of SVC \( O_2 \) saturation >70% by use of blood transfusion to a hemoglobin of 10 g/dL and inotropic support to increase \( CO \) resulted in a 40% reduction in mortality compared with a group in whom MAP and central venous pressure were maintained at usual target values without attention to SVC \( O_2 \) saturation (84). Since 2002, Oliveira et al (13) reproduced this finding in children with septic shock reducing mortality from 39% to 12% when directing therapy to the goal of \( ScvO_2 \) saturation >70% (NNT 3.6).

In VLBW infants, SVC blood flow measurement was reportedly useful in assessing the effectiveness of shock therapies. The SVC flow approximates blood flow from the brain. A value >40 mL/kg/min is associated with improved neurologic outcomes and survival (78–82). \( ScvO_2 \) saturation can be used in low birth weight infants but may be misleading in the presence of left to right shunting through the patent ductus arteriosus.

Intravascular Access. Vascular access for fluid resuscitation and inotrope/vasopressor infusion is more difficult to attain in newborns and children compared with adults. To facilitate a rapid approach to vascular access in critically ill infants and children, the American Heart Association and the American Academy of Pediatrics developed neonatal resuscitation program and PALS guidelines for emergency establishment of intravascular support (85, 86). Essential age-specific differences include use of umbilical artery and umbilical venous access in newborns, and rapid use of intravenous access in children. Ultrasound guidance may have a role in the placement of central lines in children.

Fluid Therapy. Several fluid resuscitation trials have been performed since 2002. For example, several randomized trials showed that when children with mostly stage III (narrow pulse pressure/tachycardia) and some stage IV (hypotension) World Health Organization classification dengue shock received fluid resuscitation in the emergency department, there was near 100% survival regardless of the fluid composition used (6, 9, 87, 88). In a randomized controlled trial, Maidland et al (10) demonstrated a reduction in malaria septic shock mortality from 18% to 4% when albumin was used compared with crystalloid. The large randomized adult SAFE trial that compared crystalloid vs. albumin fluid resuscitation reported a trend toward improved outcome (p < 0.1) in septic shock patients who received albumin (89). Preference for the exclusive use of colloid resuscitation was made based on a clinical practice position article from a group who reported outstanding clinical results in resuscitation of meningococcal septic shock (5% mortality) both using 4% albumin exclusively (20 mL/kg boluses over 5–10 mins) and intubating and ventilating all children who required greater than 40 mL/kg (7). In an Indian trial of fluid resuscitation of pediatric septic shock, there was no difference in outcome with gelatin compared with crystalloid (90). In the initial clinical case series...
that popularized the use of aggressive volume resuscitation for reversal of pediatric septic shock, a combination of crystalloid and colloid therapies was used (91). Several new investigations examined both the feasibility of the 2002 guideline recommendation of rapid fluid resuscitation as well as the need for fluid removal in patients with subsequent oliguria after fluid resuscitation. The 2002 guideline recommended rapid 20 mL/kg fluid boluses over 5 mins followed by assessment for improved perfusion or fluid overload as evidenced by new onset rales, increased work of breathing, and hypoxemia from pulmonary edema, hepatomegaly, or a diminishing MAP—central venous pressure. Emergency medicine investigators reported that 20 mL/kg of crystalloid or colloid can be pushed over 5 mins, or administered via a pressure bag over 5 mins through a peripheral and/or central IV line (92). Ranjit et al (93) reported improved outcome from dengue and bacterial septic shock when they implemented a protocol of aggressive fluid resuscitation followed by fluid removal using diuretics and/or peritoneal dialysis if oliguria ensued. In this regard, Poland et al (94) similarly reported that patients with multiple organ failure who received CRRT when they were <10% fluid overloaded had better outcomes than those who were >10% fluid overloaded. Similarly, two best outcome practices reported routine use of CRRT to prevent fluid overload while correcting prolonged INR with plasma infusion in patients with purpura and septic shock (7, 15).

The use of blood as a volume expander was examined in two small pediatric observational studies, but no recommendations were given by the investigators (95, 96). In the previously mentioned study by Oliveira et al (13) reporting improved outcome with use of the 2002 ACCM guidelines and continuous Scvo_{2} saturation monitoring, the treatment group received more blood transfusions directed to improvement of Scvo_{2} saturation to >70% (40% vs. 7%). This finding agrees with the results of Rivers (84) who transfused patients with a SVC oxygen saturation <70% to assure a hemoglobin of 10 g/dL as part of goal-directed therapy based on central venous oxygen saturation. Although the members of the task force use conservative goals for blood transfusion in routine critical illness, the observations that for patients with septic shock, transfusion to a goal hemoglobin >10 g/dL to achieve Scvo_{2} >70% is associated with increased survival suggests that this higher hemoglobin goal is warranted in this population.

Fluid infusion is best initiated with boluses of 20 mL/kg, titrated to assuring an adequate blood pressure and clinical monitors of CO including HR, quality of peripheral pulses, capillary refill, level of consciousness, peripheral skin temperature, and urine output. Initial volume resuscitation commonly requires 40—60 mL/kg but can be as much as 200 mL/kg (28, 91, 97—104). Patients who do not respond rapidly to initial fluid boluses, or those with insufficient physiologic reserve, should be considered for invasive hemodynamic monitoring. Monitoring filling pressures can be helpful to optimize preload and thus CO. Observation of little change in the central venous pressure in response to a fluid bolus suggests that the venous capacitance system is not overfilled and that more fluid is indicated. Observation that an increasing central venous pressure is met with reduced MAP—central venous pressure suggests that too much fluid has been given. Large volumes of fluid for acute stabilization in children have not been shown to increase the incidence of the acute respiratory distress syndrome (91, 103) or cerebral edema (91, 104). Increased fluid requirements may be evident for several days secondary to loss of fluid from the intravascular compartment when there is profound capillary leak (28). Routine fluid choices include crystalloids (normal saline or lactated Ringers) and colloids (dextran, gelatin, or 5% albumin) (6, 105—114). Fresh frozen plasma may be infused to correct abnormal prothrombin time and partial thromboplastin time values, but should not be pushed because it may produce acute hypotensive effects likely caused by vasoactive kinins and high citrate concentration. Because oxygen delivery depends on hemoglobin concentration, hemoglobin should be maintained at a minimum of 10 g/dL (13, 84). Diuretics/peritoneal dialysis/CRRT are indicated for patients who develop signs and symptoms of fluid overload.

**Mechanical Ventilation.** There are several reasons to initiate intubation and ventilation in relation to the hemodynamic support of patients with septic shock. In practice, the first indication is usually the need to establish invasive hemodynamic monitoring. In uncooperative, coagulopathic infants, this is most safely accomplished in the sedated, immobile patient. This step should be considered in any patient who is not rapidly stabilized with fluid resuscitation and peripherally administered inotropes.

Ventilation also provides mechanical support for the circulation. Up to 40% of CO may be required to support the work of breathing, and this can be unloaded by ventilation, diverting flow to vital organs. Increased intrathoracic pressure also reduces left ventricular afterload that may be beneficial in patients with low CI and high SVR. Ventilation may also provide benefits in patients with elevated pulmonary vascular resistance. Mild hyperventilation may also be used to compensate for metabolic acidosis by altering the respiratory component of acid-base balance. Caution must be exercised as excessive ventilation may impair CO, particularly in the presence of hypovolemia. Additional volume loading is often necessary at this point.

Sedation and ventilation also facilitate temperature control and reduce oxygen consumption. Importantly but less commonly, ventilation is required because of clinical and laboratory evidence of respiratory failure, impaired mental state, or moribund condition.

**Sedation for Invasive Procedures or Intubation.** Airway and breathing can initially be managed according to PALS guidelines using head positioning, and a high flow oxygen delivery system. A report published since 2002 supports early management of dengue shock using high flow nasal cannula O_{2}/continuous positive airway pressure (115). When intubation or invasive procedures are required, patients are at risk of worsening hypotension from the direct myocardial depressant and vasodilator effects of induction agents as well as indirect effects due to blunting of endogenous catecholamine release. Propofol, thiopental, benzodiazepines, and inhalational agents all carry these risks. Yamamoto (116) and others (7, 15) suggest using ketamine with atropine premedication for sedation and intubation in septic shock. Ketamine is a central NMDA receptor blocker, which blocks nuclear factor-kappa B transcription and reduces systemic interleukin-6 production while maintaining an intact adrenal axis, which in turn maintains cardiovascular stability (117–125). Ketamine can also be used as a sedation/analgies infusion to maintain cardiovascular stability during mechanical ventilation (126). Etomidate is popular as
an induction agent because it maintains cardiovascular stability through blockade of the vascular K+ channel; however, even one dose used for intubation is independently associated with increased mortality in both children and adults with septic shock, possibly secondary to inhibition of adrenal corticosteroid biosynthesis. Therefore, it is not recommended for this purpose (127–131). Only one member of the task force continues to support use of etomidate in pediatric septic shock with the caveat that stress dose hydrocortisone be administered. Little has been published on the use of ketamine or etomidate in newborns with shock so we cannot make recommendations for or against the use of these drugs in newborns. When intubation and ventilation are required the use of neuromuscular blocking agents should be considered.

**Intravascular Catheters and Monitoring.** Minimal invasive monitoring is necessary in children with fluid-responsive shock; however, central venous access and arterial pressure monitoring are recommended in children with fluid-refractory shock. Maintenance of perfusion pressure (MAP—central venous pressure), or (MAP—IAP) if the abdomen is tense secondary to bowel edema or ascitic fluid, is considered necessary for organ perfusion (38). Echocardiography is considered an appropriate noninvasive tool to rule out the presence of pericardial effusion, evaluate contractility, and depending on the skills of the echocardiographer, check ventricular filling. Doppler echocardiography can be used to measure CO and SVC flow. CO >3.3 L/min/m² <6.0 L/min/m² and SVC flow >40 mL/kg/min in newborns are associated with improved survival and neurologic function. Goal-directed therapy to achieve an ScvO₂ saturation >70% is associated with improved outcome (13). To gain accurate measures of ScvO₂, the tip of the catheter must be at or close to the SVC-right atrial or inferior vena cava-right atrial junction (132). A pulmonary artery catheter, pulse index contour cardiac output catheter estimates global end-diastolic volume in the heart (both chambers) and extravascular lung water and can be used to assess whether preload is adequate. None of these techniques is possible in neonates and smaller infants. Other noninvasive monitors undergoing evaluation in newborns and children include percutaneous venous oxygen saturation, aortic ultrasound, perfusion index (pulsioxmetry), near infrared spectroscopy, sublingual Pco₂, and sublingual microvascular orthogonal polarization spectroscopy scanning. All show promise; however, none have been tested in goal-directed therapy trials (145–152).

**Cardiovascular Drug Therapy**

When considering the use of cardiovascular agents in the management of infants and children with septic shock, several important points need emphasis. The first is that septic shock represents a dynamic process so that the agents selected and their infusion dose may have to be changed over time based on the need to maintain adequate organ perfusion. It is also important to recognize that the vasoactive agents are characterized by varying effects on SVR and pulmonary vascular resistance (i.e., vasodilators or vasoressors), contractility (i.e., inotropic) and HR (chronotropy). These pharmacologic effects are determined by the pharmacokinetics of the agent and the pharmacodynamics of the patient’s response to the agent. In critically ill septic children, perfusion and function of the liver and kidney are often altered, leading to changes in drug pharmacokinetics with higher concentrations observed than anticipated. Thus, the infusion doses quoted in many textbooks are approximations of starting rates and should be adjusted based on the patient’s response. The latter is also determined by the pharmacodynamic response to the agent, which is commonly altered in septic patients. For example, patients with sepsis have a well-recognized reduced response to alpha-adrenergic agonists that is mediated by excess NO production as well as alterations in the alpha-adrenergic receptor system. Similarly, cardiac beta-adrenergic responsiveness may be reduced by the effect of NO and other inflammatory cytokines.

**Inotropes**

Dopamine (5–9 µg/kg/min), dobutamine, or epinephrine (0.05–0.3 µg/kg/min) can be used as first-line inotropic support. Dobutamine may be used when there is a low CO state with adequate or increased SVR (29, 84, 153–165). Dobutamine or mid-dose dopamine can be used as the first line of inotropic support if supported by clinical and objective data (e.g., assessment of contractility by echocardiogram) when one of the initial goals is to increase cardiac contractility in patients with normal blood pressure. However, children <12 months may be less responsive (161). Recent adult data raises the concern of increased mortality with the use of dopamine (166). There is not a clear explanation for these observations. Possible explanations include the action of a dopamine infusion to reduce the release of hormones from the anterior pituitary gland, such as prolactin, through stimulation of the DA_2 receptor, which can have important immunoprotective effects, and inhibition of thyrotropin releasing hormone release. Adult data favors the use of norepinephrine as a first line agent in fluid-refractory vasodilated (and often hypotensive) septic shock (167–170). Although the majority of adults with fluid-refractory, dopamine-resistant shock have high CO and low SVR, children with this condition predominantly have low CO.

Dobutamine- or dopamine-refractory low CO shock may be reversed with epinephrine infusion (29, 171–174). Epinephrine is more commonly used in children than in adults. Some members of the committee recommended use of low-dose epinephrine as a first-line choice for cold hypodynamic shock. It is clear that epinephrine has potent inotropic and chronotropic effects, but its effects on peripheral vascular resistance and the endocrine stress response may result in additional problems. At lower infusion doses (<0.3 µg/kg/min) epinephrine has greater beta-2-adrenergic effects in the peripheral vasculature with little alpha-adrenergic effect so that SVR falls, particularly in the skeletal musculature and skin. This may redirect blood flow away from the splanchnic circulation even though blood pressure and CO increases. This effect of epinephrine likely explains the observation that epinephrine transiently reduces gastric intramucosal pH in adults and animals with hyperdynamic sepsis (175), but there are no data avail-
able to evaluate whether gut injury does or does not occur with epinephrine use in children. Epinephrine stimulates gluconeogenesis and glycogenolysis, and inhibits the action of insulin, leading to increased blood glucose concentrations. In addition, as part of the stimulation of gluconeogenesis, epinephrine increases the shuffle of lactate to the liver as a substrate for glucose production (the Cori cycle). Thus, patients on epinephrine infusion have increased plasma lactate concentrations independent of changes in organ perfusion, making this parameter somewhat more difficult to interpret in children with septic shock.

Ideally, epinephrine should be administered by a secure central venous route, but in an emergency it may be infused through a peripheral IV route or through an intraosseous needle while attaining central access. The American Heart Association/PALS guidelines for children recommends the initial use of epinephrine by peripheral IV or intravenous for cardiopulmonary resuscitation or post-cardiopulmonary resuscitation shock, and by the intramuscular route for anaphylaxis (176). Even though a common perception, there is no data clarifying if the peripheral infiltration of epinephrine produces more local damage than observed with dopamine. The severity of local symptoms likely depends on the concentration of the vasoactive drug infiltration and the duration of the peripheral infiltration before being discovered. If peripheral infiltration occurs with any catecholamine, its adverse effects may be antagonized by local subcutaneous infiltration with phentolamine, 1–5 mg diluted in 5 mL of normal saline.

**Vasodilators**

When pediatric patients are normotensive with a low CO and high SVR, initial treatment of fluid-refractory patients consists of the use of an inotropic agent such as epinephrine or dobutamine that tends to lower SVR. In addition, a short-acting vasodilator may be added, such as sodium nitroprusside or nitroglycerin to recruit microcirculation (177–182) and reduce ventricular afterload resulting in better ventricular ejection and global CO, particularly when ventricular function is impaired. Orthogonal polarizing spectroscopy showed that addition of systemic IV nitroglycerin to dopamine/norepinephrine infusion restored tongue microvascular blood flow during adult septic shock (183). Nitrovasodilators can be titrated to the desired effect, but use of nitroprusside is limited if there is reduced renal function secondary to the accumulation of sodium thiocyanate; use of nitroglycerin may also have limited utility over time through the depletion of tissue thiols that are important for its vasodilating effect. Other vasodilators that have been used in children include prosta cyclin, pentoxifylline, dopexamine, and fenoldopam (184–189).

An alternative approach to improve cardiac contractility and lower SVR is based on the use of type III phosphodiesterase inhibitors (PDEIs) (190–196). This class of agents, which includes milrinone and inamrinone (formerly amrinone, but the name was changed to avoid confusion with amiodarone), has a synergistic effect with beta-adrenergic agonists since the latter agents stimulate intracellular cyclic adenosine monophosphate (cAMP) production, whereas the PDEIs increase intracellular cAMP by blocking its hydrolysis. Because the PDEIs do not depend on a receptor mechanism, they maintain their action even when the beta-adrenergic receptors are down-regulated or have reduced functional responsiveness. The main limitation of these agents is their need for normal renal function (for milrinone clearance) and liver function (for inamrinone clearance). Inamrinone and milrinone are rarely used in adults with septic shock because catecholamine refractory low CO and high vascular resistance is uncommon; however, this hemodynamic state represents a major proportion of children with fluid-refractory, dopamine-resistant shock. Fluid boluses are likely to be required if inamrinone or milrinone are administered with full loading doses. Because milrinone and inamrinone have long half lives (1–10 hrs depending on organ function) it can take 3–30 hrs to reach 90% of steady state if no loading dose is used. Although recommended in the literature some individuals in the committee choose not to use boluses of inamrinone or milrinone. This group administers the drugs as a continuous infusion only. Other members divide the bolus in five equal aliquots administering each aliquot over 10 mins if blood pressure remains within an acceptable range. If blood pressure falls, it is typically because of the desired vasodilation and can be reversed by titrated (e.g., 5 mL/kg) boluses of isotonic crystallloid or colloid. Because of the long elimination half-life, these drugs should be discontinued at the first sign of arrhythmia, or hypotension caused by excessively diminished SVR. Hypotension-related toxicity can also be potentially overcome by beginning norepinephrine or vasopressin. Norepinephrine counteracts the effects of increased cAMP in vascular tissue by stimulating the alpha receptor resulting in vasoconstriction. Norepinephrine has little effect at the vascular β2 receptor.

Rescue from refractory shock has been described in case reports and series using two medications with type III phosphodiesterase activity. Levosimendan is a promising new medication that increases Ca2+/actin/tropomyosin complex binding sensitivity and also has some type III PDEI and adenosine triphosphate-sensitive K+ channel activity. Because one of the pathogenic mechanisms of endotoxin-induced heart dysfunction is desensitization of Ca2+/actin/tropomyosin complex binding (197–202), this drug allows treatment at this fundamental level of signal transduction overcoming the loss of contractility that characterizes septic shock. Enoximone is a type III PDEI with 10 times more β2 cAMP hydrolysis inhibition than β2 cAMP hydrolysis inhibition (203–205). Hence, it can be used to increase cardiac performance with less risk of undesired hypotension.

**Vasopressor Therapy**

Dopamine remains the first-line vasopressor for fluid-refractory hypotensive shock in the setting of low SVR. However, there is some evidence that patients treated with dopamine have a worse outcome than those treated without dopamine (206) and that norepinephrine, when used exclusively in this setting, leads to adequate outcomes (188). There is also literature demonstrating an age-specific insensitivity to dopamine (207–216). Dopamine causes vasoconstriction by releasing norepinephrine from sympathetic vesicles as well as acting directly on alpha-adrenergic receptors. Immature animals and young humans (<6 months) may not have developed their full component of sympathetic innervation so they have reduced releasable stores of norepinephrine. Dopamine-resistant shock commonly responds to norepinephrine or high-dose epinephrine (29, 217–219). Some committee members advocate the use of low-dose norepinephrine as a first-line agent for fluid-refractory hypotensive hyperdynamic shock. Based on experi-
Low-dose arginine vasopressin (in
sor with no beta-adrenergic activity
sion. The effect of low-dose argi-

nitine vasopressin on clinically important
outcomes such as mortality remains un-
certain. The Vasopressin and Septic
Shock Trial, a randomized controlled
clinical trial that compared low-dose ar-
ginine vasopressin with norepinephrine
in patients with septic shock, showed no
difference between regimens in the 28-
day mortality primary end point (236).
The safety and efficacy of low-dose argi-
nine vasopressin have yet to be demon-
strated in children with septic shock, and
await the results of an ongoing random-
ized controlled trial (237, 238).

Glucose, Calcium, Thyroid, and Hy-
drocortisone Replacement. It is impor-
tant to maintain metabolic and hormonal
homeostasis in newborns and children.
Hypoglycemia can cause neurologic dev-
estation when missed. Therefore, hypo-
glycemia must be rapidly diagnosed and
promptly treated. Required glucose infu-
sion rates for normal humans are age
specific but can be met by delivering a
D10%-containing solution at mainte-
nance fluid rates (8 mg/kg/min glucose in
newborns, 5 mg/kg/min glucose in chil-
dren, and 2 mg/kg/min in adolescents).
Patients with liver failure will require
higher glucose infusion rates (up to 16
mg/kg/min). Hyperglycemia is also a risk
factor for mortality. Lin and Carcillo
(239) reported that children with septic
shock, who had hyperglycemia (>140
mg/dL) and an elevated anion gap,
showed resolution of their anion gap
when insulin was added to their glucose
regimen. This was associated with rever-
sal of catabolism as measured by urinary
organic acids. Infants with metabolic dis-
ease are particularly vulnerable to cata-
bolic failure and must be treated with an
appropriate glucose delivery, and when
needed insulin to assure glucose uptake,
during septic shock. It is important to
note that insulin requirements decrease
at approximately 18 hrs after the onset of
shock. Infusion of insulin and glucose are
also effective inotropes. Two members of
the task force preferred using D5%-g/dL. Nonsurvi-

Copyright (c) Society of Critical Care Medicine and Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
dosing if desired. The treatment should be weaned off as tolerated to minimize potential long-term toxicities.

Administration of prolonged hydrocortisone and fludrocortisone (6 mg/kg/day cortisol equivalent × 7 days) had been recommended for adults with dopamine-resistant septic shock and relative adrenal insufficiency (basal cortisol >18 μg/dL with cortisol increment after corticotropin stimulation <9 μg/dL) (260); however, adult guidelines now recommend this therapy for any adult with dopamine-resistant septic shock. The continuing debate on whether this should similarly be an adjunctive therapy for pediatric sepsis will likely only be resolved with yet-to-be done pediatric trials. Since 2002, a randomized trial of a 7-day course of 3 mg/kg/day of intermittent hydrocortisone therapy for dopamine-treated septic shock in premature babies was performed. These babies had reduced dopamine requirements but no improvement in mortality (58, 262, 264). Unlike dexamethasone, which was associated with neurologic consequences in premature babies (261), hydrocortisone did not cause similar complications in premature babies (263).

Multiple pediatric studies conducted over the interval 1999–2006 provide consistent evidence that children who succumbed from septic shock exhibited lower cortisol levels than those who survived, and that septic shock nonsurvivors had lower random plasma cortisol concentrations compared with septic shock survivors; the latter had lower random plasma cortisol concentrations compared with sepsis survivors (254, 255, 265–267). This effect is not attributable to inadequate ACTH adrenal stimulation; on the contrary, an opposite trend prevails, namely septic shock nonsurvivors exhibit high circulating ACTH concentrations compared with septic shock survivors, who in turn have higher circulating ACTH concentrations compared with patients with sepsis. One retrospective cohort study using the Pediatric Health Information System database examined factors associated with outcome in children with severe sepsis as operationally identified by a combination of infection plus need for vasoactive infusion and mechanical ventilation (268). Among 6693 children meeting the definition of severe sepsis, mortality was 30% for children who received steroids compared with 18% for those who did not (crude odds ratio 1.9) (95% confidence interval 1.7–2.2). An important liability of this investigation relates to lack of illness severity data. Although steroids may have been given preferentially to more severely ill children, their use was associated with increased mortality. Steroid use was linked to disseminated candidiasis in a case report (269). The committee continues to maintain equipoise on the question of adjunctive steroid therapy for pediatric sepsis (outside of classic adrenal or hypophyseal pituitary axis (HPA) axis insufficiency), pending prospective randomized clinical trials.

**Persistent Pulmonary Artery Hypertension of the Newborn Therapy.** Inhaled NO therapy is the treatment of choice for uncomplicated PPHN (270, 271). However, metabolic alkalinization remains an important initial resuscitative strategy during shock because PPHN can reverse when acidosis is corrected (272). For centers with access to inhaled NO, this is the only selective pulmonary vasodilator reported to be effective in reversal of PPHN (270, 271, 273–278). Milrinone or inamrinone may be added to improve heart function as tolerated (279–281). ECMO remains the therapy of choice for patients with refractory PPHN and sepsis (282–285). New investigations support use of inhaled iloprost (sustained analog of prostacyclin) or adenosine infusion as modes of therapy for PPHN (286–291).

**Extracorporeal Therapies.** ECMO is not routinely used in adults (with the notable exception of the University of Michigan) (282). ECMO is a viable therapy for refractory septic shock in neonates (283) and children because neonates (approximately 80% survival) and children (approximately 50% survival) (292–295) have the same outcomes whether the indication for ECMO is refractory respiratory failure or refractory shock from sepsis or not. It is also effective in adult hantavirus victims with low CO/high SVR shock (296, 297). Although ECMO survival is similar in pediatric patients with and without sepsis, thrombotic complications can be more common in sepsis. Efforts are warranted to reduce ECMO-induced hemolysis because free heme scavenges NO, adenosine, and a disintegrin and metalloprotease with thrombospondin motifs-13 (ADAMTS-13; von Willebrand factor cleaving protease) leading to microvascular thrombosis, reversal of portal blood flow and multiple organ failure (298, 299). Nitroglycerin (NO donor), adenosine, and fresh frozen plasma (FFP) (ADAMTS-13) can be infused to attempt to neutralize these effects. Hemolysis can be avoided, in part, by using the proper-sized cannula for age and limiting ECMO total blood flow to no greater than 110 mL/kg/min. Additional CO can be attained using inotrope/vasopressor therapies.

Investigators also reported that the use of high flux CRRT (>35 mL/kg/h filtration-dialysis flux), with concomitant FFP or antithrombotic protein C infusion to reverse prolonged INR without causing fluid overload, reduced inotrope/vasopressor requirements in children with refractory septic shock and purpura (7, 15, 300–305). The basis of this beneficial effect remains unknown. It could result from prevention of fluid overload, clearance of lactate and organic acids, binding of inflammatory mediators, reversal of coagulopathy, or some combination of these actions.

**RECOMMENDATIONS**

**Pediatric Septic Shock**

**Diagnosis:** The inflammatory triad of fever, tachycardia, and vasodilation are common in children with benign infections (Fig. 1). Septic shock is suspected when children with this triad have a change in mental status manifested as irritability, inappropriate crying, drowsiness, confusion, poor interaction with parents, lethargy, or becoming unarousable. The clinical diagnosis of septic shock is made in children who 1) have a suspected infection manifested by hypothermia or hyperthermia, and 2) have clinical signs of inadequate tissue perfusion including any of the following; decreased or altered mental status, prolonged capillary refill >2 secs (cold shock), diminished pulses (cold shock) mottled cool extremities (cold shock) or flash capillary refill (warm shock), bounding peripheral pulses, and wide pulse pressure (warm shock) or decreased urine output <1 ml/kg/h. Hypotension is not necessary for the clinical diagnosis of septic shock; however, its presence in a child with clinical suspicion of infection is confirmatory.

**ABCs: The First Hour of Resuscitation (Emergency Room Resuscitation)**

**Goals:** (Level III). Maintain or restore airway, oxygenation, and ventilation (Table 1); maintain or restore circulation, defined
Figure 1. Algorithm for time sensitive, goal-directed stepwise management of hemodynamic support in infants and children. Proceed to next step if shock persists. 1) First hour goals—Restore and maintain heart rate thresholds, capillary refill in infants and children. Proceed to next step if shock persists. 1) First hour goals—Restore and maintain normal perfusion and blood pressure; 2) Intensive care unit goals—if shock is not reversed, intervene to restore and maintain normal perfusion and blood pressure due to low DBP) and high SVR. In early sepsis, patients often have a respiratory alkalosis from centrally mediated hyperventilation. As sepsis progresses, patients may have hypoxemia as well as metabolic acidosis and are at high risk to develop respiratory acidosis secondary to a combination of parenchymal lung disease and/or inadequate respiratory effort due to altered mental status. The decision to intubate and ventilate is based on clinical assessment of increased work of breathing, hypoventilation, or impaired mental status. Waiting for confirmatory laboratory tests is discouraged. Up to 40% of CO is used for work of breathing. Therefore, intubation and mechanical ventilation can reverse shock. If possible, volume loading and peripheral or central inotropic/vasoactive drug support is recommended before and during intubation because of relative or absolute hypovolemia, cardiac dysfunction, and the risk of suppressing endogenous stress hormone response with agents that facilitate intubation. Etomidate is not recommended. Ketamine with atropine pretreatment and benzodiazepine postintubation can be used as a sedative/induction regimen of choice to promote cardiovascular integrity. A short-acting neuromuscular blocker can facilitate intubation if the provider is confident she/he can maintain airway patency.

Circulation (Level II). Vascular access should be rapidly attained. Establish intravenous access if reliable venous access cannot be attained in minutes. Fluid resuscitation should commence immediately unless hemodynamically/rales are present. Recall that rales may be heard in children with pneumonia as a cause of sepsis, so it does not always imply that the patient is fluid overloaded. If pneumonia is suspected or confirmed, fluid resuscitation should proceed with careful monitoring of the child's work of breathing and oxygen saturation. In the fluid-refractory patient, begin a peripheral inotrope (low-dose dopamine or epinephrine) if a second peripheral IV/intraosseous catheter is in place, while establishing a central venous line. When administered through a peripheral IV/intraosseous catheter, the inotrope should be infused either as a dilute solution or with a second carrier solution running at a flow rate to assure that it reaches the heart in a timely fashion. Care must be taken to reduce dosage if evidence of peripheral infiltration/ischemia occurs as alpha-adrenergic receptor-mediated effects occur at higher concentrations for epinephrine and dopamine. Central dopamine, epinephrine, or norepinephrine can be administered as a first line drug as indicated by hemodynamic state when a central inotropic/vasoactive drug support is possible, volume loading and peripheral or central inotropic/vasoactive drug support is recommended before and during intubation because of relative or absolute hypovolemia, cardiac dysfunction, and the risk of suppressing endogenous stress hormone response with agents that facilitate intubation. Etomidate is not recommended. Ketamine with atropine pretreatment and benzodiazepine postintubation can be used as a sedative/induction regimen of choice to promote cardiovascular integrity. A short-acting neuromuscular blocker can facilitate intubation if the provider is confident she/he can maintain airway patency.

Therapeutic End Points (Level III). Capillary refill ≤2 sec, normal pulses with no differential between the quality of peripheral and central pulses, warm extremities, urine output >1 mL/kg/h, normal mental status, normal blood pressure for age (noninvasive blood pressure only reliable when pulses palpable), normal glucose concentration, normal ionized calcium concentration.

Monitoring (Level III). Pulse oximeter, continuous electrocardiography, blood pressure and pulse pressure. Note pulse pressure and diastolic pressure to help distinguish between low SVR (wide pulse pressure due to low DBP) and high SVR (narrow pulse pressure). Temperature, urine output, glucose, ionized calcium.

Airway and Breathing (Level III). Airway and breathing should be rigorously monitored and maintained. Lung compliance and work of breathing may change precipitously. In early sepsis, patients often have a respiratory alkalosis from centrally mediated hyperventilation. As sepsis progresses, patients may have hypoxemia as well as metabolic acidosis and are at high risk to develop respiratory acidosis secondary to a combination of parenchymal lung disease and/or inadequate respiratory effort due to altered mental status. The decision to intubate and ventilate is based on clinical assessment of increased work of breathing, hypoventilation, or impaired mental status. Waiting for confirmatory laboratory tests is discouraged. Up to 40% of CO is used for work of breathing. Therefore, intubation and mechanical ventilation can reverse shock. If possible, volume loading and peripheral or central inotropic/vasoactive drug support is recommended before and during intubation because of relative or absolute hypovolemia, cardiac dysfunction, and the risk of suppressing endogenous stress hormone response with agents that facilitate intubation. Etomidate is not recommended. Ketamine with atropine pretreatment and benzodiazepine postintubation can be used as a sedative/induction regimen of choice to promote cardiovascular integrity. A short-acting neuromuscular blocker can facilitate intubation if the provider is confident she/he can maintain airway patency.

Circulation (Level II). Vascular access should be rapidly attained. Establish intravenous access if reliable venous access cannot be attained in minutes. Fluid resuscitation should commence immediately unless hemodynamically/rales are present. Recall that rales may be heard in children with pneumonia as a cause of sepsis, so it does not always imply that the patient is fluid overloaded. If pneumonia is suspected or confirmed, fluid resuscitation should proceed with careful monitoring of the child’s work of breathing and oxygen saturation. In the fluid-refractory patient, begin a peripheral inotrope (low-dose dopamine or epinephrine) if a second peripheral IV/intraosseous catheter is in place, while establishing a central venous line. When administered through a peripheral IV/intraosseous catheter, the inotrope should be infused either as a dilute solution or with a second carrier solution running at a flow rate to assure that it reaches the heart in a timely fashion. Care must be taken to reduce dosage if evidence of peripheral infiltration/ischemia occurs as alpha-adrenergic receptor-mediated effects occur at higher concentrations for epinephrine and dopamine. Central dopamine, epinephrine, or norepinephrine can be administered as a first line drug as indicated by hemodynamic state when a central inotropic/vasoactive drug support is possible, volume loading and peripheral or central inotropic/vasoactive drug support is recommended before and during intubation because of relative or absolute hypovolemia, cardiac dysfunction, and the risk of suppressing endogenous stress hormone response with agents that facilitate intubation. Etomidate is not recommended. Ketamine with atropine pretreatment and benzodiazepine postintubation can be used as a sedative/induction regimen of choice to promote cardiovascular integrity. A short-acting neuromuscular blocker can facilitate intubation if the provider is confident she/he can maintain airway patency.
and wait until a pharmacologic effect is observed before stopping the peripheral infusion.

Fluid Resuscitation (Level II). Rapid fluid boluses of 20 mL/kg (isotonic crystalloid or 5% albumin) can be administered by push or rapid infusion device (pressure bag) while observing for signs of fluid overload (i.e., the development of increased work of breathing, rales, gallop rhythm, or hepatomegaly). In the absence of these clinical findings, repeated fluid boluses can be administered to as much as 200 mL/kg in the first hour. Children commonly require 40–60 mL/kg in the first hour. Fluid can be pushed with the goal of attaining normal perfusion and blood pressure. Hypoglycemia and hypocalcemia should be corrected. A D10%-containing isotonic IV solution can be run at maintenance IV fluid rates to provide age-appropriate glucose delivery and to prevent hypoglycemia.

Hydrocortisone Therapy (Level III). If a child is at risk of absolute adrenal insufficiency or adrenal pituitary failure (e.g., purpura fulminans, congenital adrenal hyperplasia, prior recent steroid exposure, hypothalamic/pituitary abnormality) and remains in shock despite epinephrine or norepinephrine infusion, then hydrocortisone can be administered ideally after attaining a blood sample for subsequent determination of baseline cortisol concentration. Hydrocortisone may be administered as an intermittent or continuous infusion at a dosage which may range from 1–2 mg/kg/day for stress associated with surgery, trauma, or severe infection.

Therapeutic End Points: (Level III). Capillary refill ≤2 secs, threshold HRs, normal pulses with no differential between the quality of the peripheral and central pulses, warm extremities, urine output >1 mL/kg/h, normal mental status, CI >3.3 and <6.0 L/min/m² with normal perfusion pressure (MAP – central venous pressure, or MAP – IAP) for age, ScvO₂ >70%; maximize preload to maximize CI, MAP – central venous pressure; normal INR, anion gap, and lactate.

Monitoring (Level III). Pulse oximetry, continuous electrocardiogram, continuous intra-arterial blood pressure, temperature (core), urine output, central venous pressure/O₂ saturation and/or pulmonary artery pressure/O₂ saturation, CO, glucose and calcium, INR, lactate, and anion gap.

Fluid Resuscitation (Level II). Fluid losses and persistent hypovolemia secondary to diffuse capillary leak can continue for days. Ongoing fluid replacement should be directed at clinical end points including perfusion, central venous pressure, echocardiographic determination of end-diastolic volume, pulmonary capillary wedge pressure/end-diastolic volume (when available), and CO. Crystalloid is the fluid of choice in patients with hemoglobin >10 g/dL. Red blood cell transfusion can be given to children with hemoglobin <10 g/dL. FFP is recommended for patients with prolonged INR but as an infusion, not a bolus. After shock resuscitation, diuretics/peritoneal dialysis/high flux CRRT can be used to remove fluid in patients who are 10% fluid overloaded and unable to maintain fluid balance with native urine output/extrarenal losses.

Elevated lactate concentration and anion gap measurement can be treated by assuring both adequate oxygen delivery and glucose utilization. Adequate oxygen delivery (indicated by a ScvO₂ >70%) can be achieved by attaining hemoglobin >10 g/dL and CO >3.3 L/min/m² using adequate volume loading and isotropic/vasodilator support when needed (as described below). Appropriate glucose delivery can be attained by giving a D10% containing isotonic IV solution at fluid maintenance rate. Appropriate glucose uptake can be attained in subsequently hyperglycemic patients by titrating an insulin infusion to reverse hyperglycemia (keep glucose concentration ≤150 mg/dL) while carefully monitoring to avoid hypoglycemia (keep glucose concentration ≥80 mg/dL). The use of lesser glucose infusion rates (e.g., D5% or lower volumes of D10%) will not provide glucose delivery requirements.

Hemodynamic support (Level II). Hemodynamic support can be required for days in children with fluid-refractory dopamine resistant shock. Children with catecholamine-resistant shock can present with low CO/high SVR, high CO/low SVR, or low CO/low SVR shock. Although children with persistent shock commonly have worsening cardiac failure, hemodynamic states may completely change with time. A pulmonary artery, pulse index contour cardiac output, or femoral artery thermodilution catheter, or Doppler ultrasound should be used when poor perfusion, including reduced urine output, acidosis, or hypotension persists despite use of hemodynamic therapies guided by clinical examination, blood pressure analysis, and arterial and ScvO₂ analysis. Children with catecholamine-resistant shock can respond to a change in hemodynamic therapeutic regimen with resolution of shock. Therapies should be directed to maintain mixed venous/ScvO₂ >70%, CI >3.3 L/min/m² <6.0 L/min/m², and a normal perfusion pressure for age (MAP-central venous pressure).

Shock with Low CI, Normal Blood Pressure, and High Systemic Vascular Resistance (Level II). This clinical state is similar to that seen in a child with cardiogenic shock in whom afterload reduction is a mainstay of therapy designed to improve blood flow by reducing ventricular afterload and thus increasing ventricular emptying. Thus, nitroprusside or nitroglycerin is first line vasodilators in patients with epinephrine-resistant septic shock and normal blood pressure. If cyanide or isothiocyanate toxicity develops from nitroprusside, or methemoglobin toxicity develops from nitroglycerin, or there is a continued low CO state, then the clinician should substitute milrinone or levosimendan and enoximone may have a role in recalcitrant low CO syndrome. Thyroid replacement with triiodothyronine is warranted for thyroid insufficiency, and

Stabilization: Beyond the First Hour (Pediatric Intensive Care Unit Hemodynamic Support)

Goals: (Level III). Normal perfusion; capillary refill ≤2 secs, threshold HRs. Perfusion pressure (MAP – central venous pressure, or MAP – IAP) appropriate for age. ScvO₂ >70%; CI >3.3 L/min/m² and <6.0 L/min/m².

Copyright (c) Society of Critical Care Medicine and Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
hydrocortisone replacement can be warranted for adrenal or hypothalamic-pituitary-adrenal axis insufficiency.

**Shock with Low CI, Low Blood Pressure, and Low Systemic Vascular Resistance (Level II).** Norepinephrine can be added to epinephrine to increase DBP and SVR. Once an adequate blood pressure is achieved, dobutamine, type III PDEI (particularly enoximone, which has little vasodilatory properties), or levosimendan can be added to norepinephrine to improve CI and ScvO2. Thyroid replacement with triiodothyronine is warranted for thyroid insufficiency, and hydrocortisone replacement is warranted for adrenal or hypothalamic-pituitary-adrenal axis insufficiency.

**Shock with High CI and Low Systemic Vascular Resistance (Level II).** When titration of norepinephrine and fluid does not resolve hypotension, then low dose vasopressin, angiotensin, or terlipressin can be helpful in restoring blood pressure; however, these potent vasoconstrictors can reduce CO, therefore it is recommended that these drugs are used with CO/ScvO2 monitoring. In this situation, additional inotropic therapies may be required, such as low-dose epinephrine or dobutamine, or the vasopressor infusion may be reduced. Terlipressin is a longer-acting drug than angiotensin or vasopressin so toxicities are more long acting. As with other forms of severe shock, thyroid hormone or adrenocortical replacement therapy may be added for appropriate indications.

**Refractory Shock (Level II).** Children with refractory shock must be suspected to have one or more of the following sometimes occult morbidities (treatment in parenthesis), including pericardial effusion (periocardiocentesis), pneumothorax (thoracentesis), hypoadrenalism (adrenal hormone replacement), hypothyroidism (thyroid hormone replacement), ongoing blood loss (blood replacement/hemostasis), increased IAP (peritoneal catheter, or abdominal release), necrotic tissue (nidus removal), inappropriate source control of infection (remove nidus and use antibiotics with the lowest minimum inhibitory concentration possible, preferably <1, use IV immunoglobulin for toxic shock), excessive immunosuppression (weak immunosuppressants), or immune compromise (restore immune function; e.g., white cell growth factors/transfusion for neutropenic sepsis). When these potentially reversible causes are addressed, ECMO becomes an important alternative to consider. Currently, however, the expected survival with ECMO is no greater than 50%. If the clinician suspects that outcome will be better with ECMO, flows greater than 110 mL/kg/min should be discouraged as they may be associated with hemolysis. Measure free hemoglobin and maintain concentration <10 μg/dL by using adequate catheter, circuit, and oxygenator sizes for age. Calcium concentration should be normalized in the red blood cell pump prime (usually requires 300 mg CaCl2 per unit of packed red blood cells). Additional venous access may be required if ECMO flow is <110 mL/kg/min with a negative pressure <−25 mm Hg. This may require the addition of intrathoracic drainage as well. Cannula placement should be checked using both chest radiograph and ultrasound guidance. High flux CRRT (>35 mL/kg/h) should also be considered, particularly in patients at risk for fluid overload, with septic shock and purpura. This extracorporeal therapy can reduce inotrope/vasopressor needs within 6 hrs of use.

**Newborn Septic Shock**

**Diagnosis.** Septic shock should be suspected in any newborn with tachycardia, respiratory distress, poor feeding, poor tone, poor color, tachypnea, diarrhea, or reduced perfusion, particularly in the presence of a maternal history of chorioamnionitis or prolonged rupture of membranes (Fig. 2). It is important to distinguish newborn septic shock from cardiogenic shock caused by closure of the patent ductus arteriosus in newborns with ducal-dependent complex congenital heart disease. Any newborn with shock and hepatomegaly, cyanosis, a cardiac murmur, or differential upper and lower extremity blood pressures or pulses should be started on prostaglandin infusion until complex congenital heart disease is ruled out by echocardiographic analysis. Inborn errors of metabolism resulting in hyperammonemia or hypoglycemia may simulate septic shock and appropriate laboratory tests should be obtained to rule out these conditions. Newborn septic shock is typically accompanied by increased pulmonary vascular resistance and artery pressures. PPHN can cause right ventricle failure with right to left shunting at the atrial/ductal levels causing cyanosis.

**ABCs: The First Hour of Resuscitation (Delivery Room Resuscitation)**

**Goals: (Level III).** Maintain airway, oxygenation, and ventilation; restore and maintain circulation, defined as normal perfusion and blood pressure; maintain neonatal circulation; and maintain threshold HRs.

**Therapeutic End Points (Level III).** Capillary refill ≤2 secs, normal pulses with no differential in quality between peripheral and central pulses, warm extremities, urine output >1 mL/kg/h, normal mental status, normal blood pressure for age, normal glucose, and calcium concentrations.

**Difference in preductal and postductal O2 saturation ≤5%.**

**95% arterial oxygen saturation.**

**Monitoring (Level III).** Temperature, preductal and postductal pulse oximetry, intra-arterial (umbilical or peripheral) blood pressure, continuous electrocardiogram, blood pressure, arterial pH, urine output, and glucose, ionized calcium concentration.

**Airway and Breathing (Level III).** Airway patency and adequate oxygenation and ventilation should be rigorously monitored and maintained. The decision to intubate and ventilate is based on clinical diagnosis of increased work of breathing, inadequate respiratory effort, marked hypoxemia, or a combination of these abnormalities. Volume loading is often necessary before intubation and ventilation because positive pressure ventilation can reduce preload.

**Circulation (Level III).** Vascular access can be rapidly attained according to neonatal resuscitation program guidelines. Placement of an umbilical arterial and venous line is preferred.

**Fluid Resuscitation (Level II).** Fluid boluses of 10 mL/kg can be administered, observing for the development of hepatomegaly and increased work of breathing. Up to 60 mL/kg may be required in the first hour. Fluid should be infused with a goal of attaining normal perfusion and blood pressure. A D10%-containing isotonic IV solution run at maintenance rate will provide age appropriate glucose delivery to prevent hypoglycemia.

**Hemodynamic Support (Level II).** Patients with severe shock uniformly require cardiovascular support during fluid resuscitation. Although dopamine can be used as the first-line agent, its effect on pulmonary vascular resistance should be
considered. A combination of dopamine at low dosage (<8 μg/kg/min) and dobutamine (up to 10 μg/kg/min) is initially recommended. If the patient does not adequately respond to these interventions, then epinephrine (0.05–0.3 μg/kg/min) can be infused to restore normal blood pressure and perfusion.

Persistent Pulmonary Hypertension Therapy (Level II). Hyperoxygenate initially with 100% oxygen and institute metabolic alkalization (up to pH 7.50) with NaHCO₃ or tromethamine until inhaled NO is available. Mild hyperventilation to produce a respiratory alkalosis can also be instituted at 100% O₂ saturation and <5% difference in preductal and postductal saturations are obtained. Inhaled NO should be administered as the first treatment when available.

Stabilization: Beyond the First Hour (Neonatal Intensive Care Unit Hemodynamic Support)

Goals: (Level III). Restore and maintain threshold HR; maintain normal perfusion and blood pressure; maintain neonatal circulation; ScvO₂ >70%; CI >3.3 L/min/m²; SVC flow >40 mL/kg/min.

Therapeutic End points (Level III). Capillary refill ≤2 sec, normal pulses with no differential between peripheral and central pulses, warm extremities, urine output >1 mL/kg/h, normal mental status, normal blood pressure for age, >95% arterial oxygen saturation, <5% difference in preductal and postductal arterial oxygen saturation.

ScvO₂ >70%.

Absence of right-to-left shunting, tricuspid regurgitation, or right ventricular failure on echocardiographic analysis.

Normal glucose and ionized calcium concentrations.

SVC flow >40 mL/kg/min.

CI >3.3 L/min/m².

Normal INR.

Normal anion gap and lactate.

Fluid overload <10%.

Monitoring (Level III). Pulse oximetry, blood gas analysis, electrocardiogram, continuous intra-arterial blood pressure, temperature, glucose and calcium concentration, “ins and outs,” urine output, central venous pressure/O₂ saturation, CO, SVC flow, INR, and anion gap and lactate.

Fluid Resuscitation (Level II). Fluid losses and persistent hypovolemia secondary to diffuse capillary leak can continue for days. Ongoing fluid replacement should be directed at clinical end points, including perfusion and central venous pressure. Crystalloid is the fluid of choice in neonates with hemoglobin >12 g/dL. Packed red blood cells can be transfused in newborns with hemoglobin <12 g/dL. Diuretics or CRRT is recommended in newborns who are 10% fluid overloaded and unable to attain fluid balance with native urine output/extrarenal losses. A D10%-containing isotonic IV solution run at maintenance rate can provide age appropriate glucose delivery to prevent hypoglycemia. Insulin infusion can be used to correct hyperglycemia. Diuretics are indicated in hypervolemic patients to prevent fluid overload.

Hemodynamic Support (Level II). A 5-day, 6-hr per day course of IV pentoxifylline can be used to reverse septic shock in VLBW babies. In term newborns with PPHN, inhaled NO is often effective. Its greatest effect is usually observed at 20 ppm. In newborns with poor left ventricle function and normal blood pressure, the addition of nitrovasodilators or type III phosphodiesterase inhibitors to epinephrine (0.05–0.3 μg/kg/min) can be effective but must be monitored for toxicities.
It is important to volume load based on clinical examination and blood pressure changes when using these systemic vasodilators. Triiodothyronine is an effective inotrope in newborns with thyroid insufficiency. Norepinephrine can be effective for refractory hypotension but ScvO₂ should be maintained >70%. An additional inotropic therapy should be added if warranted. Hydrocortisone therapy can be added if the newborn has adrenal insufficiency (defined by peak cortisol <18 µg/dL, or basal cortisol <18 µg/dL in an appropriately volume-loaded patient requiring epinephrine). The rescue use of vasopressin, terlipressin, or angiotensin can be considered in the presence of adequate CO, SVC flow, and/or ScvO₂ monitoring.

ACKNOWLEDGMENTS

Approval Committee—Andrew Argent (South Africa), Anton (Indonesia), Ronaldo Arkader (Sao Paolo, Brazil), Debbie Bills, RN (Pittsburgh, PA), Desmond J. Bohn, MBBS (Toronto, Canada), Booy (London, England), Robert Boxer, MD (Roslyn, NY), George Briassoulis (Crete, Greece), Joe Brieley (London, England), Richard Brillii, MD (Cincinnati, OH), Cynthia W. Broner, MD (Columbus, OH), Tim Bunchman (Grand Rapids, MI), Warwick Butt (Melbourne, Australia), Hector Carillo (Mexico City, Mexico), Juan Casado-Flores, MD (Spain), Billy Casey (Dublin, Ireland), Leticia Castillo, MD (Boston, MA), Gary D. Ceneviva, MD (Hershey, PA), Karen Choong (Ontario, Canada), Paolo Cogo (London, England), Andrew T. Costarino, MD (Wilmington, DE), Peter Cross (Toronto, Canada), Heidi J. Dalton, MD (Washington, DC), Alan L. Davis, MD (Summit, NJ), M. den Brinker (Rotterdam, The Netherlands), DeKLesing (Rotterdam, NE), Lesley A. Doughty, MD (Providence, RI), Michelle Dragotta, RN (Pittsburgh, PA), Trevor Duke (Melbourne, Australia), Alan W. Duncan (Perth, Australia), J.R. Evans (Philadelphia, PA), N. Evans (Sydney, Australia), Elizabeth A. Farrington, PharmD (Durham, NC), Timothy F. Feltes, MD (Columbus, OH), Kate Felmel (Pittsburgh, PA), Melinda Fieder (Pittsburgh, PA), Jason Folan (Atlanta, GA), James Fortenberry (Atlanta, GA), Brett P. Giroir, MD (Dallas, TX), Brahun Goldstein, MD (Portland, OR), Bruce Greenwald, MD (New York, NY), Mark Hall, MD (Columbus, OH), Yong Y. Han (Ann Arbor, MI), Steven E. Haun, MD (Sioux City, SD), Gabriel J. Hauser, MD (Washington, DC), Jan Hazlejedt, MD (Rotterdam, The Netherlands), Sabrina Heidemann, MD (Detroit, MI), Lynn Herran, MD (Buffalo, NY), Ronald B. Hirsch, MD (Ann Arbor, MI), Steven A. Hollenberg, MD (Chicago, IL), Jorge Irazusta, MD (Boston, MA), Brian Jacobs, MD (Cincinnati, OH), Stephen R. Johnson, MD (Los Angeles, CA), K.F. Joosten (Rotterdam The Netherlands), Robert Kanter, MD (Syracuse, NY), Carol King, MD (Buffalo, NY), Bulent Karapinar (Izmir, Turkey), Erica Kirsch, MD (Dallas, TX), M. Kluckow (Sydney, Australia), Martha Kukto (New York, NY), Jacques LaCroix, MD (Montreal, Canada), Stephen A. Lawless, MD (Wilmington, DE), Lauterbach (Poland), Francis LeClerc, MD (Lille, France), Michael Levon (London, England), John Lin (San Antonio, TX), Steven E. Lucking, MD (Hershey, PA), Lucy Lum, MD (Kuala Lampur, Malaysia), Kath Maitland (Kilif, Kenya), Michele Mariscalco, MD (Houston, TX), I. Mastok (Hashomer, Israel), Cris Mangia (Sao Paolo, Brazil), F.O. Odetola (Ann Arbor, MI), Jean-Christophe Mercier (Paris, France), Richard B. Mink (Los Angeles, CA), M. Michelle Moss, MD (Little Rock, AR), C. Munter (London, England), A.I. Murdoch (London, England), P.C. Ng (Hong Kong), Ninis (London, England), Daniel A. Notterman, MD (Newark, NJ), William Novotny (Greenville, NC), Claudio Oliveira (Sao Paolo, Brasil), D. Osborn (Sydney, Australia), Kristan M. Outwater, MD (Saginaw, MI), J.F. Padbury (Providence, RI), Hector S. Pabon, MD (Brandon, FL), Margaret M. Parker, MD (Stonybrook, NY), J. Alan Passchell, MD (Tokoma, WA), Andy Petros (London, England), Jefferson P. Piva (Porto Alegre, Brazil), Ronal M. Perkins, MD (Greenville, NC), Pajled (London, England), Francois Prouk (Montreal, Canada), J. Ranjit (Chennai, India), E.M. Reynolds (Boston, MA), Francois Ronco, MD (Santiago, Chile), Cathy H. Rosenthal-Dichter, MN, CCRN (Yorktown, IN), James Royall, MD (Oklahoma City, OK), Ivstov Sani (Los Angeles, CA), Thomas Shanley (Ann Arbor, MI), Billie L. Short, MD (Washington, DC), Sunit Singh (Chandigarh, India), Peter Skippin (Vancouver, BC), N.V. Subhadar (Liverpool, England), Rod Tarrago (Minneapolis/St. Paul, MN), Neal Thomas (Hershey, PA), S.M. Tibby (London, England), Joseph Tobias (Columbia, MO), Scott Watson (Pittsburgh, PA), Willis (London, England), Arno Zaritsky (Gainesville, FL), Jerry Zimmerman (Seatle, WA).

ECMO and CRRT Therapy for Refractory Shock (Level II)

Newborns with refractory shock must be suspected to have unrecognized morbidities (requiring specific treatment) including pericardial effusion (pericardio-centesis), pneumothorax (thoracentesis), ongoing blood loss (blood replacement/hemostasis), hypoadrenalism (hydrocortisone), hypothyroidism (triiodothyronine), inborn errors of metabolism (responsive to glucose and insulin infusion or ammonia scavengers), and/or cyanotic or obstructive heart disease (responsive to prostaglandin E₁), or a critically large patent ductus arteriosus (patent ductus arteriosus closure). When these causes have been excluded, ECMO becomes an important therapy to consider in term newborns. The current ECMO survival rate for newborn sepsis is 80%. Most centers accept refractory shock or a PaO₂ <40 mm Hg after maximal therapy to be sufficient indication for ECMO support. ECMO flows greater than 110 mL/kg should be discouraged because hemolysis can ensue. With venovenous ECMO, persistent hypotension and/or shock should be treated with dopamine/dobutamine or epinephrine. Inotropic requirements frequently diminish when veno-arterial ECMO is used but not always. Calcium concentration should be normalized in the red blood cell pump prime (usually requires 300 mg CaCl₂ per unit of packed red blood cells). In newborns with inadequate urine output and 10% fluid overload despite diuretics, CRRT is best performed while on the ECMO circuit.

5. Carcillo JA, Fields Al: American College of Critical Care Medicine Task Force Commit-
tee Members: Clinical practice parameters for hemodynamic support of pediatric and

drome: A randomized double-blind comparison of 4 intravenous fluid regimens in the

coccal Research Group: Reduction in case fatality rate from meningococcal disease as-
associated with improved healthcare delivery. *Arch Dis Child* 2001; 85:386–390


9. Wills BA, Nguyen MD, Ha TL, et al: Com-
parison of the three fluid solutions for re-

albumin or saline in children with severe malaria: Preliminary evidence of albumin ben-

11. Han YY, Carcillo JA, Dragotta MA, et al: Early reversal of pediatric-neonatal septic shock by community physicians is associ-
ated with improved outcome. *Pediatrics* 2003; 112:793–799

ningococcal disease in children: Case-
control study of fatal and non-fatal cases. *BMJ* 2005; 330:1475

13. de Oliveira CF, de Oliveira DS, Gottschald AF, et al: ACCM/PALS haemodynamic sup-
port guidelines for paediatric septic shock: An outcomes comparison with and without
monitoring central venous oxygen satu-
ration. *Intensive Care Med* 2008; 34: 1065–1075

14. Karapinar B, Lin JC, Carcillo JA: ACCM guidelines use, correct antibiotic therapy, and
immune suppressant withdrawal are as-

15. Maat M, Buysse CM, Emonts M, et al: Im-
proved survival in children with sepsis and
vors and nonsurvivors of human septic shock: Heart rate as an early predictor of


20. Lichtenstein GR, Gussin DA, Backus R: Multiple organ dysfunction in septic shock

21. Pollack MM, Fields AI, Ruttimann UE: Dis-
cardiovascular functions in pediatri patients and survivors of seps-


26. Walther JF, Siassi B, Ramadan NA: Cardiac output in newborn infants with transient

27. Ferdman B, Jureidini SB, Mink BB: Severe left ventricular dysfunction and arrhyth-
mias as complication of gram positive sep-
sis: Rapid recovery in children. *Pediatr Car-
diol* 1998; 19:482–486

vors and nonsurvivors of human septic shock: Heart rate as an early predictor of

29. Green EM, Adams HR: New perspectives in cir-
culatory shock: Pathophysiologic mediators of the mammalian response to endo-

30. McDonald RR, Brumfield BA, Lang CH: In vitro myocardial performance after lethal and

severe systolic and diastolic cardiac dys-
fuction in a canine model that simulates

32. Briery J, Thiruchelvan T, Peters MJ: Hemo-
dynamics of early pediatric fluid resistant septic shock using non-invasive cardiac
output (USCOM) distinct profiles of CVC infection and community acquired sepsis.
*Crit Care Med* 2006; 33:171–1


34. Sosa G, Milstein JM, Bennett SH: *E. coli*
endotoxin depresses left ventricular con-

35. Pevey KJ, Chatrand SA, Wiseman HJ, et al: Myocardial dysfunction in group B strepto-

36. Meadow WL, Meus PJ: Unsuspected mesen-
teric hypoperfusion despite apparent hemo-
dynamic recovery in the early phase of sep-

37. Meadow WL, Meus PJ: Early and late hemo-
dynamic consequences of group B beta streptococcal sepsis in piglets: Effects on systolic, pulmonary, and mesenteric circu-

38. Gill AB, Wendling AM: Echocardiographic
assessment of cardiac function in shocked
very low birthweight infants. *Arch Dis Child* 1993; 68(1 Spec No):17–21

39. Kluckow M: Low systemic blood flow and

40. Munro MJ, Walker AM, Barfield CP: Hype-
tensive extremely low birth weight infants have reduced cerebral blood flow. *Pediatrics* 2004; 114:1591–1596

41. Jayasinghe D, Gill AB, Levene MI: CBF re-
activity in hypotensive and normotensive

42. Vavilala MS, Lam AM: CBF reactivity to changes in MAP (cerebral autoregulation)
or CO2 (CO2 reactivity) is lost in hypoten-
sive, ventilated, preterm infants. *Pediatr
Res* 2004; 55:898–899

43. Al-Aweel I, Pursley DM, Rubin LP, et al: Variations in prevalence of hypertension, hy-


45. Subbedar NV: Treatment of hypertension in
newborns. *Semin Neonatol* 2003; 8:413–423

46. Seri I, Noori S: Diagnosis and treatment of
neonatal hypertension outside the transit-


48. Evans JR, Lou Short B, Van Meurs K,
79. Evans N, Osborn D, Kluckow M: Mechanism of blood pressure increase induced by dopamine in hypotensive perterm neonates. Arch Dis Child Fetal Neonatal Ed 2000; 83:F75–F76
97. Carrol CG, Snyder JV: Hyperdynamic severe
intravascular sepsis depends on fluid ad-
ministration in cyonomolgous monkey. Am J
Physiol 1982; 243:R31–R141
98. Lee PK, Derringer JR, Kreiswirth BN, et al: 
Fluid replacement protection of rabbits 
challenged subcutaneous with toxic shock 
syndrome toxins. Infect Immun 1991; 59: 
879–884
Cardiac output and organ blood flow in 
experimental septic shock and treatment with 
antibiotics, corticosteroids, and fluid infusion. 
100. Hohen LD, Paschall JA, Eckstein J, et al: 
Awake porcine model of intraperitoneal 
sepsis and altered oxygen utilization. Circ
Shock 1991; 34:252–262
101. Wilson MA, Chec MC, Spain DA: Fluid re-
suscitation attenuates early cytokine mRNA 
expression after peritonitis. J Trauma 1996; 
41:622–627
102. Boldt J, Muller M, Heesen M: Influence of 
different volume therapies and peritoxin-
line infusion on circulating adhesion mol-
ecules in critically ill patients. Crit Care
of large volume replacement with balanced 
electrolyte solutions on extravascular lung 
space in surgical patients with sepsis syn-
drome. Intensive Care Med 1989; 15: 
505–510
Normalization of plasma arginine vaso-
presin concentrations when children with 
meningitis are given maintenance plus re-
117:515–522
105. Padyk P, Wodey E, Betremieux P: Effects of 
volume expansion on cardiac output in the 
106. Lambert HJ, Baylis PH, Coulthard MG: Cen-
tral-peripheral temperature difference, 
blood pressure, and arginine vasopressin in 
trials of normal saline versus 5% albumin for 
of hydroxylethanol starch on cardiac output in 
hypotensive neonates: A comparison with 
isotonic saline and 5% albumin. Acta Pae-
diatr 2005; 94:552–556
108. Cam BV, Tuan DT, Fonsmark L, et al: Random-
ized comparison of oxygen mask treat-
ment vs nasal continuous positive airway 
pressure in dengue shock syndrome with 
acute respiratory failure. J Trop Pediatr
1997; 43:335–339
In: Textbook of Pediatric Emergency Care.
Ludwig, S, Fleisher GR (Eds). Philadelphia, 
PA, Lippincott, Wilkins and Williams, 2000
110. Van der Linde P, Gilbart E, Engelman E, et al: 
Comparison of halothane, isoflurane, al-
fentanyl, and ketamine in experimental sep-
tic shock. Anesth Analg 1990; 70:608–617
111. Neder Meyer T, Lazaro Da Silva A: Ketamine 
reduces mortality of severely burnt rats, 
when compared to midazolam plus fenta-
112. Song XM, Wang YL, Zhou Q, et al: Protect-
ive effect of ketamine against septic shock in 
rats. Zhongguo Wei Zhuong Bing Ji Jiu 
Yi Xue 2004; 16:348–351
amine suppresses tumor necrosis factor al-
pha activity and mortality in carrageenan-
sensitized endotoxic shock model. Circ
Shock 1994; 44:160–168
114. Taniguchi T, Takemoto Y, Kanakura H, 
et al: The dose related effects of ketamine on 
mortality and cytokine response to endo-
toxin induced shock in rats. Anesth Analg 
2003; 97:1769–1772
The anti-inflammatory effects of ket-
amine in endotoxemic rats during moderate 
and mild hypothermia. Anesth Analg 2004; 
98:1114–1120
116. Taniguchi T, Shibata K, Yamamoto K: Ket-
amine inhibits endotoxin induced shock in 
rats. Anesthesiology 2001; 95:928–932
Ketamine anaesthesia in a patient with sep-
118. Modig J: Positive effects of ketamine v. me-
tomidine anesthesia on cardiovascular func-
tion, oxygen delivery and survival. Studies 
with a porcine endotoxic model. Acta Chir
Scand 1987; 153:7–13
119. Tobias J, Martin LD, Wetzel RC: Ketamine 
by continuous infusion for sedation in the 
pediatric intensive care unit. Crit Care
120. Bloomfeld R, Noble DW: Etomidate and 
may be detrimental for some patients. Br J
Anaesth 2006; 97:116–117
121. den Brinker M, Joosten KF, Liem O, et al: 
Adrenal insufficiency in meningococcal seps-
sis: Bioavailable cortisol levels and impact of 
interleukin-6 levels and intubation with 
etomidate on adrenal function and mortal-
ty. J Clin Endocrinol Metab 2005; 90: 
5109–5117
122. Jackson WL Jr: Should we use etomidate as 
an induction agent for endotracheal intuba-
tion with septic shock? A critical appraisal. 
Chest 2005; 127:1001–1008
123. Annane D: ICU physicians should abandon 
the use of etomidate! Intensive Care Med 
2005; 31:325–326
124. Morris C, Mc Allister C: Etomidate for 
emergency anesthesia; mad, bad and dan-
gerous to know? Anaesthesia 2005; 60: 
737–740
125. Fernandez EG, Green TP, Sweeney M: Low 
intravascular volume with etomidate! 
Arch Dis Child Fetal Neonatal Ed 1998; 
73:655–658
126. Tobias J, Martin LD, Wetzel RC: Ketamine 
by continuous infusion for sedation in the 
pediatric intensive care unit. Crit Care
127. Bloomfeld R, Noble DW: Etomidate and 
may be detrimental for some patients. Br J
Anaesth 2006; 97:116–117
128. den Brinker M, Joosten KF, Liem O, et al: 
Adrenal insufficiency in meningococcal seps-
sis: Bioavailable cortisol levels and impact of 
interleukin-6 levels and intubation with 
etomidate on adrenal function and mortal-
ty. J Clin Endocrinol Metab 2005; 90: 
5109–5117
129. Jackson WL Jr: Should we use etomidate as 
an induction agent for endotracheal intuba-
tion with septic shock? A critical appraisal. 
Chest 2005; 127:1001–1008
130. Annane D: ICU physicians should abandon 
the use of etomidate! Intensive Care Med 
2005; 31:325–326
131. Morris C, Mc Allister C: Etomidate for 
emergency anesthesia; mad, bad and dan-
gerous to know? Anaesthesia 2005; 60: 
737–740
Left ventricular failure complicating severe 
30:264–269
133. Zaritzky A: Aurr Concepts Pod Emerg Care
1998
134. Morrow WR, Murphy DJ Jr, Fisher DJ, et al: 
Continuous wave Doppler cardiac output: 
Use in pediatric patients receiving inotropic 
135. Duke T, Butt W, South M: Predictors of 
mortality and multiple organ failure in chil-
dren with sepsis. Intensive Care Med 1997; 
23:684–692
Continuous esophageal aortic blood flow 
echo-Doppler measurement during general 
anesthesia in infants. Can J Anaesth 1997; 
44:745–750
Clinical validation of cardiac output mea-
surement using femoral artery thermodila-
tion with direct Fick in ventilated children and 
adults. Intensive Care Med 1997; 23: 
987–991
Comparison of pulmonary artery and ther-
modilation cardiac indices in pediatric in-
85:336–338
139. Bay-Hansen R, Elving B, Greisen G: Use of 
near infrared spectroscopy for estimation of 
peripheral venous saturation in newborns:
Comparison with co-oximeter of central ve-
nous blood. Biol Neonate 2002; 82:1–8
140. Cecchetti C, Stoppa F, Vanacore N, et al: 
Monitoring of intrathoracic volemia and 
cardiac output in critically ill children. 
Minerva Anestesiol 2003; 69:907–918
ical applications of wall stress analysis in 
the pediatric intensive care unit. Crit Care
Med 2001; 29:526–533


176. The International Liaison Committee on Resuscitation (ILCOR) consensus on science with treatment recommendations for pediatric and neonatal patients: Pediatric basic and advanced life support. Pediatrics 2004; 114:1–77


188. Moffett BS, Orellana R: Use of fenoldopam to...

Copyright (c) Society of Critical Care Medicine and Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.


222. Taylor K, Holty H: Methylene blue revisited: Management of hypotension in a pedi-


atrix vasodilatory shock. Available at: http://www.controlled-trials.com/issrctn/trial/ /0/ 11597444.html


240. Drop LJ, Laver MB, Robertson NR, et al: Low plasma ionized calcium and response to cal-
tium therapy in critically ill man. Anesth-


242. Sumarmo: The role of steroids in dengue shock syndrome. Another par-


244. Ryan CA: Fatal childhood pneumococcal Waterhouse-Friedrichsen syndrome. Pediat-

245. Kohane DS: Endocrine, mineral, and meta-

246. Matot I, Sprung CL: Corticosteroids in sep-


tensive Care Med 1994; 20:489–495

249. Todd JK, Ressman M, Caston SA, et al: Cor-
ticoesteroid therapy for patients with toxic shock syndrome. JAMA 1984; 252: 3399–3402

250. Sonnenschein H, Joos HA: Hydrocortisone treatment of endotoxin shock. Another par-

251. The American Hospital Formulary 1998

252. Bettendorf M, Schmitt KG, Grulich Jenn H, et al: Tri-iodothyronine treatment in chil-
dren after cardiac surgery a double blind, randomized placebo controlled study. Lan-
cet 2000; 356:529–534

differences between survivors and non-

254. Joosten KF, deKleen ED, Westerndorp M, et al: Hypocortisolaemia and adrenocortical hormone levels in children with meningo-

255. Riordan FA, Thomson AP, Ratcliffe MJ, et al: Admission cortisol and adrenocorticotropic hormone levels in children with meningococ-


256. Soni A, Pepper GM, Wyrwinski PM, et al: Adrenal insufficiency occurring during sep-


cortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862–871

rone levels are unexpectedly low in children with acute meningococcal disease. J Clin Endocrinol Metab 2004; 89:1410–1414


263. Committee on Fetus and Newborn. Postna-

264. Seri I: Hydrocortisone and vasopressor-

265. De Kleijn ED, Joosten KF, Van Rijn B, et al: Admission plasma vasopressin levels in ad-
mission candidiasis after steroid treatment for 

dated candidiasis after steroid treatment for 


atrix severe sepsis: What is the role of ster-
roid therapy in the management of dengue 

269. Burmester M, Pierce C, Petsos A: Dissemi-

270. Roberts JD Jr, Rinnai JR, Main FC III, et al: Inhaled nitric oxide and persistent pulmo-
nary hypertension of the newborn. The In-

271. Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full term and nearly full-term 

272. Drummond WH, Gregory GA, Heyman MA, et al: The independent effects of hyperten-
vation, tolazoline, and dopamine in in-

273. Gouyon JB, Francoise M: Vasodilators in persistent pulmonary hypertension of the newborn: A need for optimal appraisal of effi-

274. Meadow WL, Meus PJ: Hemodynamic conse-


277. McNamara PJ, Laigue F, Muang-In S, et al: Milrinone improves oxygenation in neo-

sion treated with milrinone: Four case re-
ports. Biol Neonate 2006; 89:1–5

279. Rahis N, Norin FC III, Swartz DD, et al: Effects of prostacyclin and milrinone on 

280. Bartlett RH, Roloff DW, Custer JR, et al: A retrospective cohort study of prognostic factors associated with outcome in pedi-


282. Bartlett RH, Roloff DW, Custer JR, et al: A retrospective cohort study of prognostic factors associated with outcome in pedi-

Copyright (c) Society of Critical Care Medicine and Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.


285. The collaborative UK ECMO (Extracorporeal Membrane Oxygenation) trial: Follow-up to 1 year of age. *Pediatrics* 1998; 101:E1


Copyright (c) Society of Critical Care Medicine and Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.